Company Access Bio, Inc.

Equities

A950130

KR8840090003

Medical Equipment, Supplies & Distribution

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Diagnostic & Testing Substances

End-of-day quote Korea S.E. Other stock markets 23:00:00 16/06/2024 BST			5-day change	1st Jan Change
6,960 ^KRW	+3.26%		+4.82%	-22.41%

2023	Access Bio, Inc. acquired an unknown minority stake in CuraPatient Inc.	CI
2023	Tranche Update on Access Bio, Inc.'s Equity Buyback Plan announced on March 24, 2022.	CI

Access Bio, Inc. is engaged in research, development and manufacturing of in vitro rapid diagnostic tests, biosensors and molecular diagnostic products. Its product list includes covid-19 detection kits, rapid diagnostic tests, analyzers and molecular diagnostics. Its covid-19 detection kits include CareStart COVID-19 Antigen Home Test, CareStart COVID-19 Antigen, CareStart COVID-19 MDx RT-PCR, CareStart COVID-19 lgM/lgG and CareStart EZ COVID-19 lgM/lgG. Its rapid diagnostic tests include CareStart EZ HIV, CareStart Flu A&B Plus+, CareStart G6PD RDT, CareStart Malaria RDT, CareStart Dengue RDT, care US HIV 1/2 and care US Syphilis. The analyzers include care SURE Analyzer 100, care SURE A1c Cartridge, care SURE ACR Cartridge, care SURE CRP Cartridge, care START S1 Analyzer and care START G6PD Biosensor. The molecular diagnostics include care GENE HPV Screening kit-H, care GENE Zika Virus RT-PCR kit, care GENE STD detection kit, care GENE Dengue Virus genotyping kit and others.

Number of employees: 101

KRW in Million	2022	Weight	2023	Weight	Delta
Diagnostic Kits 99.7 %	-	-	348,017	99.7 %	-
Investment and Management Advisory 1.0 %	-	-	3,410	1.0 %	-
Reconciliation of Intercompany -0.7 %	-	-	-2,441	-0.7 %	-

KRW in Million	2022	Weight	2023	Weight	Delta
America 95.7 %	835,328	80.8 %	333,890	95.7 %	-60.03%
Asia 4.0 %	31,200	3.0 %	13,822	4.0 %	-55.70%
Africa 0.4 %	780	0.1 %	1,232	0.4 %	+58.03%
Europe 0.0 %	110	0.0 %	38	0.0 %	-65.95%
Oceania 0.0 %	166,566	16.1 %	5	0.0 %	-100.00%

Managers	Title	Age	Since
Young-Ho Choi CEO	Chief Executive Officer	60	31/01/02

Members of the board	Title	Age	Since
Young-Ho Choi CEO	Chief Executive Officer	60	31/01/02

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,365,847	0	2,553,998 ( 7.023 %)	-
Stock B	1	36,365,847	0	0

Name	Equities	%	Valuation
PHARMGEN SCIENCE, INC. 25.22 %	9,171,729	25.22 %	45 M ₩
ACCESS BIO, INC. 7.023 %	2,553,998	7.023 %	13 M ₩

Name	Equities	%	Valuation
ACCESS BIO, INC. 7.02%	2,553,998	7.02%	12,635,803 $

Access Bio, Inc.

65 Cylde Road Suite A

08873, Somerset

http://www.accessbio.net

Healthcare

Healthcare Services

Healthcare Equipment & Supplies

Medical Equipment, Supplies & Distribution

Diagnostic & Testing Substances

	1st Jan change	Capi.
ACCESS BIO, INC.	-22.41%	170M
BIOMÉRIEUX	-8.75%	11.5B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-7.90%	7.8B
LANTHEUS HOLDINGS, INC.	+33.27%	5.73B
AUTOBIO DIAGNOSTICS CO., LTD.	-14.93%	3.88B
ANDON HEALTH CO., LTD.	+8.42%	2.61B
10X GENOMICS, INC.	-64.30%	2.39B
VITROLIFE AB	-11.50%	2.23B
MYRIAD GENETICS, INC.	+25.55%	2.17B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-9.61%	1.76B

Diagnostic & Testing Substances